Evotec
Sara Klas is a Senior Research Scientist at Evotec since June 2019, where responsibilities include team management, project management, and data analysis for identifying novel drug targets and disease signatures in patient cohorts. Additionally, Klas interprets complex datasets and drives the development of data visualization tools. Prior experience includes a postdoctoral position at Universitätsmedizin Göttingen focused on epigenetics and gene expression in human cardiac remodeling, and a Ph.D. at Georg-August-Universität Göttingen studying the role of Hox genes in body plan specification in arthropods. Educational qualifications include a Ph.D. from the University of Göttingen and a university diploma from Stiftung Tierärztliche Hochschule Hannover.
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.